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Abstract
Introduction Phosphatidylinositol 3-kinases (PI3Ks) are a group
of lipid kinases that regulate signaling pathways involved in cell
proliferation, adhesion, survival, and motility. Even though
PIK3CA amplification and somatic mutation have been reported
previously in various kinds of human cancers, the genetic
change in PIK3CA in human breast cancer has not been clearly
identified.
Methods Fifteen breast cancer cell lines and 92 primary breast
tumors (33 with matched normal tissue) were used to check
somatic mutation and gene copy number of PIK3CA. For the
somatic mutation study, we specifically checked exons 1, 9, and
20, which have been reported to be hot spots in colon cancer.
For the analysis of the gene copy number, we used quantitative
real-time PCR and fluorescence in situ hybridization. We also
treated several breast cancer cells with the PIK3CA inhibitor
LY294002 and compared the apoptosis status in cells with and
without PIK3CA mutation.
Results We identified a 20.6% (19 of 92) and 33.3% (5 of 15)
PIK3CA somatic mutation frequency in primary breast tumors
and cell lines, respectively. We also found that 8.7% (8 of 92) of
the tumors harbored a gain of PIK3CA gene copy number. Only
four cases in this study contained both an increase in the gene
copy number and a somatic mutation. In addition, mutation of
PIK3CA correlated with the status of Akt phosphorylation in
some breast cancer cells and inhibition of PIK3CA-induced
increased apoptosis in breast cancer cells with PIK3CA
mutation.
Conclusion Somatic mutation rather than a gain of gene copy
number of PIK3CA is the frequent genetic alteration that
contributes to human breast cancer progression. The frequent
and clustered mutations within PIK3CA make it an attractive
molecular marker for early detection and a promising therapeutic
target in breast cancer.
Introduction
Phosphatidylinositol 3-kinases (PI3Ks) are a group of lipid
kinases composed of 85-kDa and 110-kDa subunits. The 85-
kDa subunit lacks PI3K activity and acts as adaptor, coupling
the 110-kDa subunit (P110) to activated protein tyrosine
kinases and generating second messengers by phosphorylat-
ing membrane inositol lipids at the D3 position. The resulting
phosphatidylinositol derivatives then permit activation of
downstream effectors that are involved in cell proliferation, sur-
vival, metabolism, cytoskeletal reorganization, and membrane
trafficking [1,2].
PIK3CA, the gene encoding the 110-kDa subunit of PI3K,
was mapped to 3q26, an area amplified in various human can-
cers including ovarian, head and neck, breast, urinary tract,
and cervical cancers [3-5]. PIK3CA was specifically found toR609
BAC = bacterial artificial chromosome; DAPI = 4',6-diamidino-2-phenylindole; FISH = fluorescence in situ hybridization; H & E = hematoxylin and 
eosin; PI3K = phosphatidylinositol 3-kinase.
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R610be amplified and overexpressed in ovarian and cervical cancer
[6-9]. The increased copy number of the PIK3CA gene is
associated with increased PIK3CA transcription, P110-alpha
protein expression, and PI3K activity in ovarian cancer [9].
Treatment with a PI3K inhibitor decreased proliferation and
increased apoptosis, suggesting that PIK3CA has an impor-
tant role in ovarian cancer. More recently, PIK3CA mutations
were identified in different human cancers. In that report,
PIK3CA was mutated in 32%, 27%, 25%, and 4% of colon,
brain, gastric, and lung cancers, respectively. Only 12 cases
of breast cancer were examined, of which one was found to
harbor a mutation in PIK3CA [10].
In an effort to identify the genetic alterations of the PIK3CA
gene in breast cancer, we determined the mutation frequency
and the change in the gene copy number of PIK3CA in a set
of primary breast tumors and breast cancer cell lines. We
found a high frequency of these somatic alterations of PIK3CA
gene in a large number of primary breast cancers. In addition,
mutation of the PIK3CA gene correlated with the activation of
Akt. Inhibition of PIK3CA induced significant apoptosis in
cells with PIK3CA mutation.
Materials and methods
Breast cancer cell line and tumors
Of the breast cancer cell lines examined, MCF12A, Hs.578t,
and MDA436 were kindly provided by Dr Nancy Davidson at
Johns Hopkins University, and MDA-MB157, MDA-MB468,
BT474, T47D, and UACC893 were kindly provided by Dr Fer-
gus J Couch at Mayo Clinic. The other cell lines were obtained
from the American Type Culture Collection. A total of 92 cases
of breast tumor, including 33 paired primary invasive breast
carcinomas and adjacent normal tissues (frozen tissue), were
obtained from the Surgical Pathology archives of the Johns
Hopkins Hospital, Baltimore, MD, USA, in accordance with the
Institutional Review Board protocol and DNA was isolated
using a standard phenol–chloroform protocol. Prof Saraswati
Sukumar at the Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins University provided isolated DNA.
Each tumor used in this study was determined to contain
greater than 70% tumor cells by H&E staining. Among these
specimens, 3 were stage 1, 52 were stage 2, 22 were stage
3, and 4 were stage 4. Eleven were of uncharacteristic stage
status. All of the tumors were high grade.
PCR, sequencing, and mutational analysis
Cell line and tumor DNA were isolated as standard protocol.
The primers we used for PCR and sequencing were as fol-
lows. For exon 1: forward, CTCCACGACCATCATCAGG,
reverse, GATTACGAAGGTATTGGTTTAGACAG, and
sequencing primer, ACTTGATGCCCCCAAGAATC; for exon
9: forward, GATTGGTTCTTTCCTGTCTCTG, reverse,
CCACAAATATCAATTTACAACCATTG, and sequencing
primer, TTGCTTTTTCTGTAAATCATCTGTG; for exon 20:
forward, TGGGGTAAAGGGAATCAAAAG, reverse, CCTAT-
GCAATCGGTCTTTGC, and sequencing primer, TGA-
CATTTGAGCAAAGACCTG. We used the same PCR
conditions for all three exons. After incubation at 95°C for 5
min, two cycles of amplification were performed at the initial
annealing temperature of 62°C, with a subsequent annealing
temperature decrease of 2°C for every two cycles until 54°C.
Twenty-five amplification cycles were then performed. After
PCR reaction, samples were subjected to automated DNA
sequencing using the ABI 377 Sequencer. The positive sam-
ples were confirmed by re-PCR and sequencing using the
same primers and conditions.
Western blotting
To evaluate Akt phosphorylation status, MDA231, MD361,
MCF7, BT20, BT474, and T47D cells were grown in appropri-
ate medium and cell lysates were collected in SDS lysis buffer
(cell signaling). Lysates were cleared of insoluble material by
microcentrifugation at 15,800 g for 15 min at 4°C, and protein
concentrations were determined (protein assay kit; Bio-Rad,
Hercules, CA, USA). Approximately 50 µg of total protein from
each sample was denatured in loading buffer for 10 min, elec-
trophoresed through 10% polyacrylamide gels, and electrob-
lotted to a nylon transfer membrane (Schleicher & Schuell,
Bioscience, Keene, NH USA). The membrane was incubated
overnight with primary antibody Akt ser473 (antirabbit, cell sig-
naling), Akt (anti rabbit, Cell signaling) or β-actin (antimouse
antibody; Sigma, St Louis, MO, USA) at 4°C. Then the mem-
brane was washed three times in Tris-buffered saline with
0.1% Tween 20 at room temperature and incubated for 1 hour
at room temperature with horseradish-peroxidase-labeled sec-
ondary antibody (goat antirabbit IgG; or goat antimouse IgG;
Sigma). Signal detection was by horseradish peroxidase
chemiluminescent reaction (ECL; Amersham).
Quantitative real-time PCR
For real-time PCR, specific primers and probes were designed
using software from Applied Biosystems (Foster City, CA,
USA) to amplify the PIK3CA and control β-actin (sequences
are available on request). Using this combination and the pro-
tocol described by Mambo and colleagues [11], the samples
were run in triplicate. Primers and probes to β-actin were run
in parallel to standardize the input DNA (4 ng). Standard
curves were developed using serial dilutions of DNA extracted
from MCF12A. PCR amplifications were performed on an ABI
7900 TaqMan (Applied Biosystems) according to the manu-
facturer's protocol.
Fluorescence in situ hybridization (FISH)
Bacterial artificial chromosome (BAC) clone RP11-466H15
for PIK3CA was obtained from Research Genetics (Invitrogen
Corporation, Carlsbad, CA, USA). BAC DNA isolation was
carried out using the standard laboratory protocol for phenol–
chloroform extraction. The chromosome 3 α-satellite plasmid
and BAC DNA were labeled directly in SpectrumOrange-
dUTP® and SpectrumGreen-dUTP® (Vysis, Downers Grove,
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(Vysis) in accordance with the manufacturer's instructions.
Slides were fixed using methanol:acetic acid (3:1), followed by
pretreatment with RNase, and dual-color FISH was performed
as described previously [12]. Slides were counterstained with
4',6-diamidino-2-phenylindole (DAPI; Sigma), mounted with
antifade (Vysis), and stored at -20°C. At least 100 nuclei were
evaluated for each sample. Analysis was carried out using an
Olympus (New Hyde Park, NY, USA) BHS fluorescence
microscope, and images were captured using a CytoVision
Ultra (Applied Imaging, Santa Clara, CA, USA).
Apoptosis detection
We assessed cellular apoptosis using an Annexin V-FITC (flu-
orescein isothiocyanate) apoptosis detection kit (BD Bio-
sciences, San Jose, CA, USA). Cells were cultured in 100-mm
dishes until 50% confluent, serum-starved overnight, and then
treated with LY294002, 3 µM and 10 µM, for 72 hours. Both
detached and adherent cells were then collected and labeled
with Annexin V-FITC and Propidium Iodide. The apoptosis was
evaluated using FACScan (Becton Dickinson ImmunoSys-
tems, Mountain View, CA, USA) flow cytometer.
Results
PIK3CA is frequently mutated in breast cancer cell lines 
and primary tumors
A previous report suggested that more than 80% of the muta-
tions of the PIK3CA gene occur in three small clusters, namely
in the p85 (exon 1), helical (exon 9) and kinase (exon 20)
domains [10]. Based on this information, we sequenced exon
1, 9, and 20 in 15 breast cancer cell lines, 92 primary tumors,
and 33 normal tissues. A total of five mutations were identified
only in the 15 breast cancer cell lines (33.3%). No mutations
were detected in the normal epithelial cell line MCF12A. Three
of the mutations were identified in exon 9 and two were found
in exon 20. No mutation was identified in exon 1. The BT20 cell
line contained two different mutations, C1616G in exon 9 and
A3140G in exon 20 (Fig. 1), corresponding to P539R and
H1047R amino acid change, respectively.
A total of 19 mutation cases (20.6%) were identified in 92 pri-
mary tumors. Six of the 19 mutations were identified in 33
tumor samples but not in their paired normal samples. This
indicated that the identified mutations are somatic mutations.
Thirteen of these 19 mutations were in exon 9, and 6 were in
exon 20. No mutation was identified in exon 1 in any of the 92
tumors. As shown in Table 1, the E545K mutation in exon 9
and the H1047R mutation in exon 20 were the two most fre-
quent mutations in both breast cancer cell lines and primary
tumors.
Gain of copy number of PIK3CA gene in primary breast 
cancer cell lines and tumors
To determine the PIK3CA gene copy number, we performed
real-time quantitative PCR on 12 breast cancer cell lines, 92
primary tumors, and 33 normal controls. Standard curves for
PIK3CA and β-actin amplification were generated using seri-
ally diluted MCF12A DNA, and showed linearity over the range
used. Fig. 2a shows the standard curve for PIK3CA amplifica-
tion with a slope of -4.044, while Fig. 2b shows the standard
curve for β-actin amplification with a slope of -3.919. We did
not observe any deletion of β-actin in the tumor samples. Most
samples showed no difference in β-actin amplification
between the paired tumor and a normal samples. A represent-
ative figure of β-actin amplification in a paired tumor and nor-
mal sample is shown in Fig. 2c. To evaluate the gene copy
number in all samples, we set the cutoff line at 4 copies.
Among the 33 cases with paired tissue, 8 (24.2%) showed a
much higher gene copy number than normal controls (Fig. 3a).
Only one case showed more than 4 copies. In a total of 92
cases of primary tumors, 8 (8.7%) had more than 4 copies,
with the highest number being 7.8 copies (Fig. 3b). In addition,
PIK3CA gene copy number was also determined in 12 breast
cancer cell lines, and the MCF7, T47D, and BT474 cell lines
had more than 4 copies (Fig. 3c). We also confirmed the gene
copy number results of these 12 cell lines with FISH analysis.
Representative FISH images are shown in Fig. 3d. Thus, our
data of gene copy analysis indicates that gene amplification/
gain of copy number of PIK3CA gene is not a frequent genetic
alteration in breast cancer.
Biological effect of PIK3CA mutations in breast cancer
To determine whether the mutation of PIK3CA correlated with
the activation of Akt (a downstream gene of PIK3 that medi-
ates carcinogenic events such as proliferation), we performed
western blot analysis to check the phosphorylation of Akt in
several breast cancer cell lines. As shown in Fig. 4a, Akt phos-
phorylation was strongest in BT20 cells (which harbor two
PIK3CA mutations) and MCF7 cells (which harbor PIK3CA
mutation and high PIK3CA gene copy numbers). We also
observed weak phosphorylation of Akt in MDA361 (which has
one mutation) and in BT474 and T47D (no observable muta-
tion but with high PIK3CA gene copy numbers). We did not
observe phosphorylation of Akt in MDA231 (Fig. 4a) or in
MCF12A and MDA157 cells (data not shown) that had no
observable mutations and no copy number gain of PIK3CA.
These data indicate that PIK3CA mutations might increase
kinase activity and in turn activate the PI3K/AKT pathway.
We further investigated the biological effects of PIK3CA
mutation in breast cancer cell lines by treating breast cancer
cells with or without PIK3CA mutation with the PIK3CA inhib-
itor LY294002. As shown in Table 1, MCF7 harbors one muta-
tion at position E545K, and BT20 harbors two mutations,
which are located at positions P539R and H1047R. These
somatic mutations were recently shown to have oncogenic
transforming activity [13]. As shown in Fig. 4b and 4c, the frac-
tions of apoptotic cells at 72 hours after treatment with 3 µM
and 10 µM LY294002 were increased in MCF7 and BT20
cells. In addition, 3 µM and 10 µM LY294002 did not induce
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(data not shown), even though serum starvation alone can
induce more than 50% apoptosis in MDA157 cells (Fig. 4c).
Discussion
This study describes two innovations. First, we show a 20.6%
mutation rate of the PIK3CA gene in breast cancer, indicating
that PIK3CA mutation is a frequent genetic alteration in breast
cancer. The 8% mutation rate of PIK3CA in breast cancer,
reported in a previous study, was underestimated [10], proba-
bly because of the smaller number of cases examined. Another
possibility might be the grade status of the tumors used, as all
of the tumors in our study were of high grade. It will be useful
and interesting in the future to explore whether PIK3CA muta-
tion is correlated with tumor grade status.
Second, CGH (comparative genomic hybridization) studies
have shown that 3q26 is an amplified chromosome region in
various cancers, including breast cancer [4,5]. Unfortunately,
it was not previously possible to identify the PIK3CA gene
Figure 1
Detection of somatic mutation of PIK3CA in breast canceri i  f I  in breast cancer. In each case, the left sequence chromatogram was obtained from normal control and the 
right sequence chromatogram was obtained from tumor. Arrows indicate the location of missense mutations. The nucleotide and amino acid altera-
tions are indicated on the left.
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Somatic mutation of PIK3CA in breast cancer cell lines and primary tumors
Exon Nucleotide Amino acid Functional domain Cell lines Tumors Total
9 C1616G P539R Helical 1 (BT20) 1
9 G1624A E542K Helical 3 3
9 G1633A E545K Helical 2 (MDA361, MCF7) 8 10
9 A1634G E545G Helical 1 1
20 A3140G H1047R Kinase 2 (BT20, UACC893) 5 5
20 A3140T H1047L Kinase 1
No. with mutations 5 19 22
No. samples screened 15 92
Percent of cases with mutations 33.3 20.6
Figure 2
Typical real-time PCR curves generated for a cell line, a tumor, and normal tissue f r  l  line, a tu or, and normal tissue. Typical standard curves generated for (a) β-actin and (b) PIK3CA 
using serial diluted DNA from cell line MCF12A. (c) Representative real-time PCR curves for β-actin, generated using paired normal and tumor DNA 
from breast tissue of one individual. Each experiment was performed in triplicate and is shown by overlapping amplification curves. ∆Rn = (Rn+) - 
(Rn-), where Rn+ is the fluorescence emission intensity of reporter/emission intensity of quencher at any time point, and Rn- is the initial emission 
intensity of reporter/emission intensity of quencher in the same reaction vessel before PCR amplification was initiated. Ct, cycle threshold.
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methods used. In our study, we used quantitative real-time
PCR, a very sensitive and far more accurate technique
[14,15], to specifically quantitate the genomic copy number of
PIK3CA not only in primary breast tumors but also in paired
tissues. Our data showed that gene amplification or gain of
PIK3CA copy number is not a frequent genetic alteration
event. This suggests that gene amplification is not the main
molecular mechanism in activating the PIK3/AKT-driven tum-
origenesis pathway in breast cancer.
Figure 3
Gain of PIK3CA gene copy number in breast cancer. (a)The change in the gene copy number of PIK3CA in 33 paired breast tissue samples. 
*Cases with significant change in gene copy number. The case number is indicated below the panel. (b) The change in the gene copy number of 
PIK3CA in 92 breast tumors and 33 normal controls. (c) Eight samples show more than 4 copies of PIK3CA. (d) The change in the gene copy 
number of PIK3CA in breast cancer cells using real-time PCR. Representative images of fluorescence in situ hybridization (FISH) analysis in various 
breast cancer cell lines. Green signals represent bacterial artificial chromosome (BAC) 466H15 probe. Red signals represent chromosome 3 cen-
tromere probe.
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alterations, including gene amplification/gain of copy number,
deletion, and mutation, were reported to be involved in the
etiology of breast cancer [16,17], our paper confirmed that
gain of gene copy number and somatic mutation of one onco-
gene exist in parallel in breast cancer. Both amplification/gain
of gene copy number and somatic mutation of PIK3CA have
been shown to be associated with increased PI3K activity and
might contribute to cancer through inhibition of apoptosis
[6,9]. Gene amplification/gain of gene copy is well accepted
as a later event in tumor progression [18,19], as is somatic
mutation [10]. To determine the relation between somatic
mutation and gain of gene copy number of PIK3CA gene in
breast cancer, we integrated our mutation and gene copy
Figure 4
Biological effect of PIK3CA mutations in breast cancer. (a) Phosphorylation (P) of Akt in breast cancer cells. Western blotting showed stronger 
phosphorylation of Akt in BT20 and MCF7 cells than in MDA 231, MDA361, BT474, or T47D. β-Actin was used as a protein loading control. (b) 
Summary of the fraction of apoptotic cell in three cell lines with different treatments (3 µM and 10 µM LY294002). [(c) Apoptosis measurement in 
which cells were stained with Annexin V-FITC and for DNA content with Propidium Iodide and analyzed using flow cytometry. Apoptotic cells appear 
as a discrete population with elevated FITC fluorescence. FITC, fluorescein isothiocyanate; SS, serum starvation
Table 2
The relation of somatic mutation and gain of copy number of PIK3CA in breast cancer
Mutation- Mutation+ Total
Gain+ 4 4 8
Gain- 69 15 84
Total 73 19 92
Fisher exact test, P = 0.054.
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had a PIK3CA gene mutation and 4 cases did not harbor a
mutation but showed a gain of gene copy number. Overall, a
quarter (23 of 92) of all breast tumors examined had either a
mutation or gain of copy number of the PIK3CA. In addition,
15 of 19 mutations were identified in tumors without gain of
copy number of PIK3CA, suggesting that somatic mutations
are a major contributory factor in the PIK3CA signaling path-
way. Only four cases in the whole study had both a mutation
and gain of copy number of PIK3CA. We did not observe a
significant association between somatic mutation and gain of
PIK3CA gene copy number in 92 cases of breast tumors
(Table 2). We suggest that further studies using larger number
of cases be undertaken in order to determine whether somatic
mutation and gene amplification are independent genetic
alterations in breast cancer.
Conclusion
The results from this study indicate that somatic mutation
rather than gene amplification of PIK3CA is the main genetic
alternation in breast cancer. The frequent and clustered muta-
tions within PIK3CA make it an attractive molecular marker for
early detection of breast cancer. In addition, the somatic muta-
tions lead to activation of PIK3CA and also correlate with the
activation of the PI3K/AKT pathway. Inhibition of PIK3CA can
significantly induce apoptosis in cells with PIK3CA mutation.
This suggests that PIK3CA might be a promising therapeutic
target in breast cancer.
(During the writing of this manuscript, Bachman KE and col-
leagues published their results in Cancer Biology and Therapy
[20]. They also reported more than 20% somatic mutations in
breast cancer, a finding consistent with this study).
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